CDAK Key Statistics, Chart & Performance
The current stock price of CDAK is 0.057 USD. In the past month the price decreased by -90.17%. In the past year, price decreased by -99%.
CDAK Latest News, Press Relases and Analysis
CDAK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.82 | 397.85B | ||
| AMGN | AMGEN INC | 15.43 | 181.73B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.52 | 107.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.67 | 78.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.29 | 60.05B | ||
| INSM | INSMED INC | N/A | 45.09B | ||
| NTRA | NATERA INC | N/A | 32.33B | ||
| BIIB | BIOGEN INC | 10.62 | 26.08B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 20.67B | ||
| INCY | INCYTE CORP | 15.89 | 20.03B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About CDAK
Company Profile
Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2020-10-14. The firm is focused on the development of exosome-based therapeutics. The firm has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. The company utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The firm's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The firm's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).
Company Info
CODIAK BIOSCIENCES INC
35 Cambridgepark Drive, Suite 500
Cambridge MASSACHUSETTS 02140 US
CEO: Douglas E. Williams
Employees: 102
Phone: 16179494100.0
CODIAK BIOSCIENCES INC / CDAK FAQ
What does CODIAK BIOSCIENCES INC do?
Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2020-10-14. The firm is focused on the development of exosome-based therapeutics. The firm has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. The company utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The firm's product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The firm's program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).
What is the stock price of CODIAK BIOSCIENCES INC today?
The current stock price of CDAK is 0.057 USD. The price decreased by -55.98% in the last trading session.
What is the dividend status of CODIAK BIOSCIENCES INC?
CDAK does not pay a dividend.
How is the ChartMill rating for CODIAK BIOSCIENCES INC?
CDAK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for CDAK stock?
CODIAK BIOSCIENCES INC (CDAK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.99).
How many employees does CODIAK BIOSCIENCES INC have?
CODIAK BIOSCIENCES INC (CDAK) currently has 102 employees.
What is the market capitalization of CDAK stock?
CODIAK BIOSCIENCES INC (CDAK) has a market capitalization of 2.10M USD. This makes CDAK a Nano Cap stock.
CDAK Technical Analysis
CDAK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CDAK. Both the profitability and financial health of CDAK have multiple concerns.
CDAK Financial Highlights
Over the last trailing twelve months CDAK reported a non-GAAP Earnings per Share(EPS) of -1.99. The EPS increased by 44.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.66 |
CDAK Forecast & Estimates
7 analysts have analysed CDAK and the average price target is 9.18 USD. This implies a price increase of 16005.26% is expected in the next year compared to the current price of 0.057.
For the next year, analysts expect an EPS growth of 41.06% and a revenue growth 61.58% for CDAK